CoChat

Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies

Open access
Privé, Bastiaan M., Boussihmad, Mohamed A., Timmermans, Bart, van Gemert, Willemijn A., Peters, Steffie M. B., Derks, Yvonne H. W., van Lith, Sanne A. M., Mehra, Niven, Nagarajah, James, Heskamp, Sandra, Westdorp, Harm · 2023 · European Journal of Nuclear Medicine and Molecular Imaging
Cited by 198

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Introduction: Fibroblast activation protein (FAP) is highly overexpressed in stromal tissue of various cancers. While FAP has been recognized as a potential diagnostic or therapeutic cancer target for decades, the surge of radiolabeled FAP-targeting molecules has the potential to revolutionize its perspective. It is presently hypothesized that FAP targeted radioligand therapy (TRT) may become a novel treatment for various types of cancer. To date, several preclinical and case series have been reported on FAP TRT using varying compounds and showing effective and tolerant results in advanced cancer patients. Here, we review the current (pre)clinical data on FAP TRT and discuss its perspective towards broader clinical implementation. Methods: A PubMed search was performed to identify all FAP tracers used for TRT. Both preclinical and clinical studies were included if they reported on dosimetry, treatment response or adverse events. The last search was performed on July 22 2022. In addition, a database search was performed on clinical trial registries (date 15 th of July 2022) to search for prospective trials on FAP TRT. Results: In total, 35 papers were identified that were related to FAP TRT. This resulted in the inclusion of the following tracers for review: FAPI-04, FAPI-46, FAP-2286, SA.FAP, ND-bisFAPI, PNT6555, TEFAPI-06/07, FAPI-C12/C16, and FSDD. Conclusion: To date, data was reported on more than 100 patients that were treated with different FAP targeted radionuclide therapies such as [177 Lu]Lu-FAPI-04, [90 Y]Y-FAPI-46, [177 Lu]Lu-FAP-2286, [177 Lu]Lu-DOTA.SA.FAPI and [177 Lu]Lu-DOTAGA.(SA.FAPi)2. In these studies, FAP targeted radionuclide therapy has resulted in objective responses in difficult to treat end stage cancer patients with manageable adverse events. Although no prospective data is yet available, these early data encourages further research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00259-023-06144-0

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Metadata

Authors
Privé, B. M., Boussihmad, M. A., Timmermans, B., van Gemert, W. A., Peters, S. M. B., Derks, Y. H. W., van Lith, S. A. M., Mehra, N., Nagarajah, J., Heskamp, S., & Westdorp, H.
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2023-02-23
Volume
50
Issue
7
Pages
1906-1918
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W4321480183
Cited by
198
References
6
FWCI
29.23
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. https://app.cochat.ai/papers/10.1007/s00259-023-06144-0
The paper
Privé, B. M., Boussihmad, M. A., Timmermans, B., van Gemert, W. A., Peters, S. M. B., Derks, Y. H. W., van Lith, S. A. M., Mehra, N., Nagarajah, J., Heskamp, S., & Westdorp, H. (2023). Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06144-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.